_id
690f3d68ccc777a4e85d1aa7
Ticker
CELUW
Name
Celularity Inc
Exchange
NASDAQ
Address
170 Park Avenue, Florham Park, NJ, United States, 07932
Country
USA
Sector
Industry
Currency
USD
Website
https://www.celularity.com
Description
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Last Close
0.0252
Volume
5320
Current Price
0.0169
Change
0.0002
Last Updated
2026-01-02T11:09:43.384Z
Image
data:image/webp;base64,UklGRkYBAABXRUJQVlA4IDoBAADwCACdASpAAEAAPrVIoEonJCMhrh25yOAWiUAPNBemDguGENs40nzxGKiVXjnfq0J+PkIyD8bCoSBZWvXTFMD85J7s7USWexve+E5EpWMu0AD++bEwdiFdrxY/AwxlPP9A3hNgBunco1cG3hbn6gKmQ2Qp1qn17L0HOfSFNHlopqTYmFy/7jNvDsXYQVxuLTqppRUWqTtt+WC0p/VI062fP6ZJeiaeDcsH6MAuvxC2DDr+P2NR1eD1fi5D1Kw5kO7p9Zrwo4zhBB669LZJP/4wFvOnc1g0Ix2DRa20ea/LkBPpZYtnb75Z50NTFTmMOKVSHWXeAkBMiNHTWJE6NgQ9UB0Nx8BQeAyDtr05obxeGb+hZR/CJbMozmYPdsdHoTELAcL52MZPPuTkisWfBYPXeuzA+Ug6QAAAAA==
Ipo Date
2019-07-19T00:00:00.000Z
Market Cap
-
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
5284000
Cost Of Revenue
2018000
Gross Profit
3266000
Operating Expenses
16166000
Operating Income
-12900000
Interest Expense
1477000
Pretax Income
-23076000
Net Income
-23073000
Eps
-0.8757081895738008
Dividends Per Share
64000
Shares Outstanding
0
Income Tax Expense
-3000
EBITDA
-19733000
Operating Margin
-244.1332323996972
Total Other Income Expense Net
-10176000
Cash
120000
Short Term Investments
-
Receivables
6705000
Inventories
2563000
Total Current Assets
10596000
Property Plant Equipment
67967000
Total Assets
114239000
Payables
24587000
Short Term Debt
5722000
Long Term Debt
-
Total Liabilities
134333000
Equity
-20094000
Bs_currency_symbol
USD
Depreciation
1824000
Change In Working Capital
6688000
Cash From Operations
-4159000
Capital Expenditures
56000
Cash From Investing
2890000
Cash From Financing
3478000
Net Change In Cash
-743000
Cf_currency_symbol
USD
PE
-
PB
-0.022159755359808898
ROE
114.8253209913407
ROA
-20.1971305771234
FCF
-4215000
Fcf Percent
-0.7976911430734293
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
0.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
6.8
Garp Investing Score
2.5
Growth Investing Score
2.5
Momentum Investing Score
4.5
Net Net Investing Score
0
Quality Investing Score
3
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
5284000
Quarters > 0 > income Statement > cost Of Revenue
2018000
Quarters > 0 > income Statement > gross Profit
3266000
Quarters > 0 > income Statement > operating Expenses
16166000
Quarters > 0 > income Statement > operating Income
-12900000
Quarters > 0 > income Statement > interest Expense
1477000
Quarters > 0 > income Statement > pretax Income
-23076000
Quarters > 0 > income Statement > net Income
-23073000
Quarters > 0 > income Statement > eps
-0.8757081895738008
Quarters > 0 > income Statement > dividends Per Share
64000
Quarters > 0 > income Statement > shares Outstanding
26347818
Quarters > 0 > income Statement > income Tax Expense
-3000
Quarters > 0 > income Statement > EBITDA
-19733000
Quarters > 0 > income Statement > operating Margin
-244.1332323996972
Quarters > 0 > income Statement > total Other Income Expense Net
-10176000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
120000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
6705000
Quarters > 0 > balance Sheet > inventories
2563000
Quarters > 0 > balance Sheet > total Current Assets
10596000
Quarters > 0 > balance Sheet > property Plant Equipment
67967000
Quarters > 0 > balance Sheet > total Assets
114239000
Quarters > 0 > balance Sheet > payables
24587000
Quarters > 0 > balance Sheet > short Term Debt
5722000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
134333000
Quarters > 0 > balance Sheet > equity
-20094000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-23076000
Quarters > 0 > cash Flow > depreciation
1824000
Quarters > 0 > cash Flow > change In Working Capital
6688000
Quarters > 0 > cash Flow > cash From Operations
-4159000
Quarters > 0 > cash Flow > capital Expenditures
56000
Quarters > 0 > cash Flow > cash From Investing
2890000
Quarters > 0 > cash Flow > cash From Financing
3478000
Quarters > 0 > cash Flow > net Change In Cash
-743000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.8757081895738008
Quarters > 0 > ratios > PB
-0.022159755359808898
Quarters > 0 > ratios > ROE
114.8253209913407
Quarters > 0 > ratios > ROA
-20.1971305771234
Quarters > 0 > ratios > FCF
-4215000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-0.7976911430734293
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
5736000
Quarters > 1 > income Statement > cost Of Revenue
5242000
Quarters > 1 > income Statement > gross Profit
494000
Quarters > 1 > income Statement > operating Expenses
16358000
Quarters > 1 > income Statement > operating Income
-15864000
Quarters > 1 > income Statement > interest Expense
1943000
Quarters > 1 > income Statement > pretax Income
-24524000
Quarters > 1 > income Statement > net Income
-24524000
Quarters > 1 > income Statement > eps
-1.0209743110723548
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
24020193
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-20747000
Quarters > 1 > income Statement > operating Margin
-276.56903765690373
Quarters > 1 > income Statement > total Other Income Expense Net
-8660000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
863000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
11152000
Quarters > 1 > balance Sheet > inventories
4410000
Quarters > 1 > balance Sheet > total Current Assets
17263000
Quarters > 1 > balance Sheet > property Plant Equipment
69441000
Quarters > 1 > balance Sheet > total Assets
120283000
Quarters > 1 > balance Sheet > payables
24400000
Quarters > 1 > balance Sheet > short Term Debt
6945000
Quarters > 1 > balance Sheet > long Term Debt
36492000
Quarters > 1 > balance Sheet > total Liabilities
145780000
Quarters > 1 > balance Sheet > equity
-25497000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-24524000
Quarters > 1 > cash Flow > depreciation
1834000
Quarters > 1 > cash Flow > change In Working Capital
14759000
Quarters > 1 > cash Flow > cash From Operations
-998999
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
1631000
Quarters > 1 > cash Flow > net Change In Cash
570000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-1.0209743110723548
Quarters > 1 > ratios > PB
-0.015921138239792913
Quarters > 1 > ratios > ROE
96.18386476840412
Quarters > 1 > ratios > ROA
-20.388583590366053
Quarters > 1 > ratios > FCF
-998999
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.17416300557880054
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
18132000
Quarters > 2 > income Statement > cost Of Revenue
7343000
Quarters > 2 > income Statement > gross Profit
10789000
Quarters > 2 > income Statement > operating Expenses
20069000
Quarters > 2 > income Statement > operating Income
-9280000
Quarters > 2 > income Statement > interest Expense
1812000
Quarters > 2 > income Statement > pretax Income
-13293000
Quarters > 2 > income Statement > net Income
-13293000
Quarters > 2 > income Statement > eps
-0.5946990584759223
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
22352482
Quarters > 2 > income Statement > income Tax Expense
13489000
Quarters > 2 > income Statement > EBITDA
-7597000
Quarters > 2 > income Statement > operating Margin
-51.18023384072359
Quarters > 2 > income Statement > total Other Income Expense Net
-4013000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
738000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
13557000
Quarters > 2 > balance Sheet > inventories
5409000
Quarters > 2 > balance Sheet > total Current Assets
20561000
Quarters > 2 > balance Sheet > property Plant Equipment
72430000
Quarters > 2 > balance Sheet > total Assets
132682000
Quarters > 2 > balance Sheet > payables
23296000
Quarters > 2 > balance Sheet > short Term Debt
6361000
Quarters > 2 > balance Sheet > long Term Debt
36492000
Quarters > 2 > balance Sheet > total Liabilities
123845000
Quarters > 2 > balance Sheet > equity
8837000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-13293000
Quarters > 2 > cash Flow > depreciation
1876000
Quarters > 2 > cash Flow > change In Working Capital
9749000
Quarters > 2 > cash Flow > cash From Operations
1594000
Quarters > 2 > cash Flow > capital Expenditures
56000
Quarters > 2 > cash Flow > cash From Investing
-1556000
Quarters > 2 > cash Flow > cash From Financing
643000
Quarters > 2 > cash Flow > net Change In Cash
681000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.5946990584759223
Quarters > 2 > ratios > PB
0.04274719314246916
Quarters > 2 > ratios > ROE
-150.42435215570896
Quarters > 2 > ratios > ROA
-10.018691307034866
Quarters > 2 > ratios > FCF
1538000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
0.08482241341275094
Quarters > 2 > health Score
23
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
18132000
Quarters > 3 > income Statement > cost Of Revenue
7343000
Quarters > 3 > income Statement > gross Profit
10789000
Quarters > 3 > income Statement > operating Expenses
27605000
Quarters > 3 > income Statement > operating Income
-9473000
Quarters > 3 > income Statement > interest Expense
1812000
Quarters > 3 > income Statement > pretax Income
-13293000
Quarters > 3 > income Statement > net Income
-13293000
Quarters > 3 > income Statement > eps
-0.5895770599570996
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
22546671
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-52.244650341936904
Quarters > 3 > income Statement > total Other Income Expense Net
-2085000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
738000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
13557000
Quarters > 3 > balance Sheet > inventories
5409000
Quarters > 3 > balance Sheet > total Current Assets
20561000
Quarters > 3 > balance Sheet > property Plant Equipment
72430000
Quarters > 3 > balance Sheet > total Assets
132682000
Quarters > 3 > balance Sheet > payables
23296000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
35927000
Quarters > 3 > balance Sheet > total Liabilities
123845000
Quarters > 3 > balance Sheet > equity
8837000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-13293000
Quarters > 3 > cash Flow > depreciation
1876000
Quarters > 3 > cash Flow > change In Working Capital
9749000
Quarters > 3 > cash Flow > cash From Operations
1594000
Quarters > 3 > cash Flow > capital Expenditures
56000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
643000
Quarters > 3 > cash Flow > net Change In Cash
681000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.5895770599570996
Quarters > 3 > ratios > PB
0.04311856284938327
Quarters > 3 > ratios > ROE
-150.42435215570896
Quarters > 3 > ratios > ROA
-10.018691307034866
Quarters > 3 > ratios > FCF
1538000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.08482241341275094
Quarters > 3 > health Score
23
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
54220000
Annuals > 0 > income Statement > cost Of Revenue
14989000
Annuals > 0 > income Statement > gross Profit
39231000
Annuals > 0 > income Statement > operating Expenses
77589000
Annuals > 0 > income Statement > operating Income
-38358000
Annuals > 0 > income Statement > interest Expense
6264000
Annuals > 0 > income Statement > pretax Income
-57892000
Annuals > 0 > income Statement > net Income
-57892000
Annuals > 0 > income Statement > eps
-2.6446153535517065
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
21890518
Annuals > 0 > income Statement > income Tax Expense
10000
Annuals > 0 > income Statement > EBITDA
-43706000
Annuals > 0 > income Statement > operating Margin
-70.74511250461084
Annuals > 0 > income Statement > total Other Income Expense Net
-19534000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
738000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
13557000
Annuals > 0 > balance Sheet > inventories
5409000
Annuals > 0 > balance Sheet > total Current Assets
20561000
Annuals > 0 > balance Sheet > property Plant Equipment
72430000
Annuals > 0 > balance Sheet > total Assets
132682000
Annuals > 0 > balance Sheet > payables
23296000
Annuals > 0 > balance Sheet > short Term Debt
6361000
Annuals > 0 > balance Sheet > long Term Debt
35927000
Annuals > 0 > balance Sheet > total Liabilities
123845000
Annuals > 0 > balance Sheet > equity
8837000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-57892000
Annuals > 0 > cash Flow > depreciation
7922000
Annuals > 0 > cash Flow > change In Working Capital
22200000
Annuals > 0 > cash Flow > cash From Operations
-6401000
Annuals > 0 > cash Flow > capital Expenditures
161000
Annuals > 0 > cash Flow > cash From Investing
514000
Annuals > 0 > cash Flow > cash From Financing
6701000
Annuals > 0 > cash Flow > net Change In Cash
814000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-2.6446153535517065
Annuals > 0 > ratios > PB
0.04012972633246577
Annuals > 0 > ratios > ROE
-655.1091999547357
Annuals > 0 > ratios > ROA
-43.63214301864608
Annuals > 0 > ratios > FCF
-6562000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-0.12102545186278126
Annuals > 0 > health Score
16
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
22771000
Annuals > 1 > income Statement > cost Of Revenue
16016000
Annuals > 1 > income Statement > gross Profit
6755000
Annuals > 1 > income Statement > operating Expenses
99250000
Annuals > 1 > income Statement > operating Income
-76479000
Annuals > 1 > income Statement > interest Expense
3015000
Annuals > 1 > income Statement > pretax Income
-196285000
Annuals > 1 > income Statement > net Income
-196295000
Annuals > 1 > income Statement > eps
-10.12970062592101
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
19378164
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-335.8614026612797
Annuals > 1 > income Statement > total Other Income Expense Net
-117111000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
227000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
10046000
Annuals > 1 > balance Sheet > inventories
5753000
Annuals > 1 > balance Sheet > total Current Assets
19793000
Annuals > 1 > balance Sheet > property Plant Equipment
78818000
Annuals > 1 > balance Sheet > total Assets
143889000
Annuals > 1 > balance Sheet > payables
14144000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
102929000
Annuals > 1 > balance Sheet > equity
40960000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-196295000
Annuals > 1 > cash Flow > depreciation
9324000
Annuals > 1 > cash Flow > change In Working Capital
3252000
Annuals > 1 > cash Flow > cash From Operations
-38685000
Annuals > 1 > cash Flow > capital Expenditures
4048000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
24094000
Annuals > 1 > cash Flow > net Change In Cash
-18639000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-10.12970062592101
Annuals > 1 > ratios > PB
0.0076642152539062505
Annuals > 1 > ratios > ROE
-479.23583984375
Annuals > 1 > ratios > ROA
-136.42113017673344
Annuals > 1 > ratios > FCF
-42733000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-1.8766413420578807
Annuals > 1 > health Score
20
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
17975000
Annuals > 2 > income Statement > cost Of Revenue
19665000
Annuals > 2 > income Statement > gross Profit
-1690000
Annuals > 2 > income Statement > operating Expenses
23910000
Annuals > 2 > income Statement > operating Income
-25600000
Annuals > 2 > income Statement > interest Expense
3171000
Annuals > 2 > income Statement > pretax Income
14205000
Annuals > 2 > income Statement > net Income
14192000
Annuals > 2 > income Statement > eps
0.947206834412334
Annuals > 2 > income Statement > dividends Per Share
39068000
Annuals > 2 > income Statement > shares Outstanding
14983000
Annuals > 2 > income Statement > income Tax Expense
13000
Annuals > 2 > income Statement > EBITDA
-138831000
Annuals > 2 > income Statement > operating Margin
-142.42002781641168
Annuals > 2 > income Statement > total Other Income Expense Net
39805000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
13966000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
6966000
Annuals > 2 > balance Sheet > inventories
5308000
Annuals > 2 > balance Sheet > total Current Assets
33502000
Annuals > 2 > balance Sheet > property Plant Equipment
88715000
Annuals > 2 > balance Sheet > total Assets
401066000
Annuals > 2 > balance Sheet > payables
5810000
Annuals > 2 > balance Sheet > short Term Debt
37603000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
202165000
Annuals > 2 > balance Sheet > equity
198901000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
14192000
Annuals > 2 > cash Flow > depreciation
9436000
Annuals > 2 > cash Flow > change In Working Capital
-15453000
Annuals > 2 > cash Flow > cash From Operations
-137876000
Annuals > 2 > cash Flow > capital Expenditures
5236000
Annuals > 2 > cash Flow > cash From Investing
-5236000
Annuals > 2 > cash Flow > cash From Financing
119838000
Annuals > 2 > cash Flow > net Change In Cash
-23274000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
0.947206834412334
Annuals > 2 > ratios > PB
0.0012203287062407932
Annuals > 2 > ratios > ROE
7.135207967782968
Annuals > 2 > ratios > ROA
3.538569711718271
Annuals > 2 > ratios > FCF
-143112000
Annuals > 2 > ratios > Piotroski FScore
2
Annuals > 2 > ratios > fcf Percent
-7.9617246175243395
Annuals > 2 > health Score
47
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
21335000
Annuals > 3 > income Statement > cost Of Revenue
9653000
Annuals > 3 > income Statement > gross Profit
11682000
Annuals > 3 > income Statement > operating Expenses
120741000
Annuals > 3 > income Statement > operating Income
-109059000
Annuals > 3 > income Statement > interest Expense
3171000
Annuals > 3 > income Statement > pretax Income
-100098000
Annuals > 3 > income Statement > net Income
-100118000
Annuals > 3 > income Statement > eps
-14.930223076483728
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
6705727
Annuals > 3 > income Statement > income Tax Expense
20000
Annuals > 3 > income Statement > EBITDA
-88110000
Annuals > 3 > income Statement > operating Margin
-511.17412702132646
Annuals > 3 > income Statement > total Other Income Expense Net
8961000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
37240000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
5233000
Annuals > 3 > balance Sheet > inventories
9549000
Annuals > 3 > balance Sheet > total Current Assets
37240000
Annuals > 3 > balance Sheet > property Plant Equipment
90625000
Annuals > 3 > balance Sheet > total Assets
414128000
Annuals > 3 > balance Sheet > payables
9317000
Annuals > 3 > balance Sheet > short Term Debt
3051000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
314710000
Annuals > 3 > balance Sheet > equity
99418000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-100118000
Annuals > 3 > cash Flow > depreciation
8817000
Annuals > 3 > cash Flow > change In Working Capital
-11083000
Annuals > 3 > cash Flow > cash From Operations
-110096000
Annuals > 3 > cash Flow > capital Expenditures
6203000
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
98562000
Annuals > 3 > cash Flow > net Change In Cash
-17437000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-14.930223076483728
Annuals > 3 > ratios > PB
0.0010926872135830533
Annuals > 3 > ratios > ROE
-100.704097849484
Annuals > 3 > ratios > ROA
-24.17561720047908
Annuals > 3 > ratios > FCF
-116299000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-5.451089758612609
Annuals > 3 > health Score
16
Valuation > metrics > PE
-0.8757081895738008
Valuation > metrics > PB
-0.022159755359808898
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
114.8253209913407
Profitability > metrics > ROA
-217.7519818799547
Profitability > metrics > Net Margin
-4.366578349735049
Profitability > final Score
40
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-8.733920108327691
Risk > final Score
-5
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.3495991289715926
Liquidity > metrics > Quick Ratio
0.2650367877528127
Liquidity > final Score
23
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
40
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-3
Prev Risks > 1
-14
Prev Risks > 2
-15
Prev Liquidities > 0
31
Prev Liquidities > 1
36
Prev Liquidities > 2
43
Updated At
2026-01-20T21:34:51.003Z
Earnings History > 0 > period
2021-06-30
Earnings History > 0 > report Date
2021-09-30
Earnings History > 0 > date
2021-06-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
USD
Earnings History > 0 > eps Actual
0.4
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
0.4
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2021-03-31
Earnings History > 1 > report Date
2021-06-30
Earnings History > 1 > date
2021-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
USD
Earnings History > 1 > eps Actual
-2.6874
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-2.6874
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-12-31
Earnings History > 2 > report Date
2021-03-31
Earnings History > 2 > date
2020-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
USD
Earnings History > 2 > eps Actual
-3.3989
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-3.3989
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-09-30
Earnings History > 3 > report Date
2020-12-31
Earnings History > 3 > date
2020-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
0.163
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
0.163
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-06-30
Earnings History > 4 > report Date
2020-09-30
Earnings History > 4 > date
2020-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-2.52
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
-2.52
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2020-03-31
Earnings History > 5 > report Date
2020-06-30
Earnings History > 5 > date
2020-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-5.6612
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-5.6612
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2019-12-31
Earnings History > 6 > report Date
2020-03-31
Earnings History > 6 > date
2019-12-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-1.2608
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-1.2608
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2019-09-30
Earnings History > 7 > report Date
2019-12-31
Earnings History > 7 > date
2019-09-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.9282
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-0.9282
Earnings History > 7 > surprise Percent
-
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AGrowth Review: Can Sunshine Biopharma Inc. Equity Warrant reach all time highs this year - July 2025 Setups & Long-Term Capital Growth Ideas baoquankhu1.vn
Read more →Will Satellogic Inc. stock benefit from commodity prices - Market Growth Summary & Technical Buy Zone Confirmation bollywoodhelpline.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of Celularity Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2021-06-30
EPS Actual
0.4
EPS Estimate
0
EPS Difference
0.4
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.